Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
2,932
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis

Deepika Reddya Imperial College, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6889-0378View further author information
ORCID Icon,
Marieke van Sonb Amsterdam University Medical Centers, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-1886-6385View further author information
ORCID Icon,
Max Petersb Amsterdam University Medical Centers, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-7981-5768View further author information
ORCID Icon,
Mariana Bertoncelli Tanakac Imperial College NHS Healthcare Trust, London, UKORCID Iconhttps://orcid.org/0000-0003-4130-6519View further author information
ORCID Icon,
Tim Dudderidged University Hospital Southampton NHS Trust, Southampton, UKORCID Iconhttps://orcid.org/0000-0001-6373-3613View further author information
ORCID Icon,
Emma Cullena Imperial College, London, UKView further author information
,
Carmen Lok Tung Hoa Imperial College, London, UKView further author information
,
Richard G. Hindleye Hampshire Hospitals NHS Foundation Trust, UK;f BMI The Hampshire Clinic, Basingstoke, UKORCID Iconhttps://orcid.org/0000-0002-7568-1694View further author information
ORCID Icon,
Amr Emarae Hampshire Hospitals NHS Foundation Trust, UKORCID Iconhttps://orcid.org/0000-0001-5619-261XView further author information
ORCID Icon,
Stuart McCrackeng Sunderland Royal Hospital, Sunderland, UKView further author information
,
Clement Orczykh University College London NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0003-3067-2409View further author information
ORCID Icon,
Iqbal Shergilli Wrexham Maelor Hospital, Wrexham, UKView further author information
,
Stephen Mangarc Imperial College NHS Healthcare Trust, London, UKView further author information
,
Raj Nigamj Royal Surrey NHS Foundation Trust, Guildford, UK;k BMI Mount Alvernia Hospital, Guildford, UKView further author information
,
Jaspal Virdil Princess Alexandra Hospital NHS Trust, Harlow, UKView further author information
,
Caroline M. Mooreh University College London NHS Foundation Trust, London, UK;m Princess Grace Hospital, London, UK;n King Edward VII Hospital, London, UKORCID Iconhttps://orcid.org/0000-0003-0202-7912View further author information
ORCID Icon,
Manit Aryac Imperial College NHS Healthcare Trust, London, UK;h University College London NHS Foundation Trust, London, UKView further author information
,
Taimur T. Shaha Imperial College, London, UK;c Imperial College NHS Healthcare Trust, London, UKORCID Iconhttps://orcid.org/0000-0003-1642-1208View further author information
ORCID Icon,
Mathias Winklera Imperial College, London, UK;c Imperial College NHS Healthcare Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-2553-5816View further author information
ORCID Icon,
Mark Embertonh University College London NHS Foundation Trust, London, UK;m Princess Grace Hospital, London, UK;n King Edward VII Hospital, London, UKORCID Iconhttps://orcid.org/0000-0003-4230-0338View further author information
ORCID Icon,
Alison Falconerc Imperial College NHS Healthcare Trust, London, UKView further author information
,
Jonathan Belseyo JB Medical Limited, Sudbury, UKORCID Iconhttps://orcid.org/0000-0001-7283-327XView further author information
ORCID Icon &
Hashim U. Ahmeda Imperial College, London, UK;c Imperial College NHS Healthcare Trust, London, UK;n King Edward VII Hospital, London, UK;p Department of Urology, Cromwell Hospital, London, UKORCID Iconhttps://orcid.org/0000-0003-1674-6723View further author information
ORCID Icon show all
Pages 1099-1107 | Received 09 May 2023, Accepted 22 Aug 2023, Published online: 08 Sep 2023

References

  • Hamdy FC, Donovan JL, Lane JA, et al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technol Assess. 2020;24(37):1–176. doi: 10.3310/hta24370.
  • Lane JA, Donovan JL, Young GJ, et al. Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study). BJU Int. 2022;130 (3):370–380. doi: 10.1111/bju.15739.
  • Reddy D, Peters M, Shah TT, et al. Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience. Eur Urol. 2022;82(3):e74–e75. doi: 10.1016/j.eururo.2022.01.005.
  • Lovegrove CE, Peters M, Guillaumier S, et al. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU evaluation and assessment of treatment (HEAT) registry. BJU Int. 2020;125(6):853–860. doi: 10.1111/bju.15004.
  • Shah TT, Peters M, Miah S, et al. Assessment of return to baseline urinary and sexual function following primary focal cryotherapy for nonmetastatic prostate cancer. Eur Urol Focus. 2021;7(2):301–308. doi: 10.1016/j.euf.2019.09.004.
  • van Son MJ, Peters M, Reddy D, et al. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer Prostatic Dis. 2021;24(4):1120–1128. doi: 10.1038/s41391-021-00369-6.
  • Shah TT, Peters M, Eldred-Evans D, et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019;76(1):98–105. doi: 10.1016/j.eururo.2018.12.030.
  • Shah TT, Ahmed H, Kanthabalan A, et al. Focal cryotherapy of localized prostate cancer: a systematic review of the literature. Expert Rev Anticancer Ther. 2014;14(11):1337–1347. doi: 10.1586/14737140.2014.965687.
  • Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042.
  • National institute for health and care excellence. Prostate cancer: diagnosis and management, London 2021.
  • Habashy D, Reddy D, Peters M, et al. Evaluation of outcomes following focal ablative therapy for treatment of localized clinically significant prostate cancer in patients >70 years: a multi-institute, multi-energy 15-year experience. J Urol. 2023;210(1):108–116. doi: 10.1097/ju.0000000000003443.
  • Noble SM, Garfield K, Lane JA, et al. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. Br J Cancer. 2020;123(7):1063–1070. doi: 10.1038/s41416-020-0978-4.
  • Andersson SO, Andren O, Lyth J, et al. Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol. 2011;45(3):177–183. doi: 10.3109/00365599.2010.545075.
  • Torvinen S, Farkkila N, Sintonen H, et al. Health-related quality of life in prostate cancer. Acta Oncol. 2013;52(6):1094–1101. doi: 10.3109/0284186X.2012.760848.
  • Protopapa E, Smith SC, Brew-Graves C, et al. TrueNth UK post surgery – urinary function in the 1st post-operative year in a 1000 man contemporary radical prostatectomy cohort. J Urol. 2018;199(4S):E739. doi: 10.1016/j.juro.2018.02.1755.
  • Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346(15):1138–1144. doi: 10.1056/NEJMsa011788.
  • Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–1437. doi: 10.1056/NEJMoa1606221.
  • Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–1261. doi: 10.1056/NEJMoa074311.
  • Prabhu V, Sivarajan G, Taksler GB, et al. Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol. 2014;65(1):52–57. doi: 10.1016/j.eururo.2013.08.006.
  • Haglind E, Carlsson S, Stranne J, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial. Eur Urol. 2015;68(2):216–225. doi: 10.1016/j.eururo.2015.02.029.
  • National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 [Internet]. London: National Institute for Health and Care Excellence (NICE); 2013 Apr 4. Process and Methods Guides No. 9.
  • Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015;19(49):1–490. doi: 10.3310/hta19490.
  • Boyd KA, Jones RJ, Paul J, et al. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open. 2015;5(10):e007925. doi: 10.1136/bmjopen-2015-007925.
  • Hu JC, Laviana A, Sedrakyan A. High-Intensity focused ultrasound for prostate cancer: novelty or innovation? JAMA. 2016;315(24):2659–2660. doi: 10.1001/jama.2016.5002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.